Next


PHARMAS HURT

17/08/22 -"Zantac and Biden seem to have taken the wind from even the strongest pharma groups' sails with the sector being the worst performer last week and down nearly 5% over the last month. So much for a ..."

Pages
50
Language
English
Published on
17/08/22
You may also be interested by these reports :
30/09/22
Our EPS estimate for 2022 and 2023 go down from PLN0.97 to PLN0.43 and PLN1.26 to PLN0.95 as we have lowered our estimates after the weak ...

30/09/22
Allegro Group’s H1 22 were strong on the top line, but weak on the EBIT and net income levels. For the first time, they reflected the results of Mall ...

29/09/22
H&M has published worse-than-expected Q3 22 profitability. The costs inflation and the stronger US dollar have put pressure on the group’s margin ...

28/09/22
There were no surprises in Ferguson’s FY21/22 performance – both organic sales and adjusted operating margin were in-line with market expectations. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO